We continue to develop nomacopan in indications that take advantage of the dual-acting properties of the drug to inhibit both C5 and LTB4.
In May 2018, we opened our first site for a six-week Phase IIa open label, single-arm trial to evaluate the safety and efficacy of nomacopan in patients with mild to moderate Bullous Pemphigoid (BP). We plan to recruit up to nine patients in study sites in Europe.
The primary endpoints of the trial are proportion of patients reporting grade 3, 4 and 5 adverse events which are related/possibly related to nomacopan during the treatment period and secondary and other endpoints include, among others, Bullous Pemphigoid Disease Area Index scores and quality of life.
In a preclinical mouse model, nomacopan demonstrated a statistically significant reduction (~60%, p=0.002) in the affected area with nomacopan compared to the vehicle and steroids.
This Phase IIa clinical trial is currently recruiting.